Edition:
United Kingdom

Bavarian Nordic A/S (BAVA.CO)

BAVA.CO on Copenhagen Stock Exchange

223.10DKK
3:59pm GMT
Change (% chg)

kr.1.20 (+0.54%)
Prev Close
kr.221.90
Open
kr.221.00
Day's High
kr.224.10
Day's Low
kr.220.80
Volume
184,449
Avg. Vol
312,911
52-wk High
kr.444.00
52-wk Low
kr.183.00

Select another date:

Mon, Jan 1 2018

Photo

Merkel's allies, further defying SPD, seek cuts to tax and asylum seeker benefits

BERLIN Germany's Bavarian conservatives are pressing for corporate tax cuts and cuts to welfare payments for asylum seekers, which could complicate talks with the Social Democrats (SPD) on forming a new government.

BRIEF-Bavarian Nordic Q3 EBIT at DKK 432 million

* Q3 EBIT DKK 432.0 ‍​ MILLION VERSUS LOSS DKK 124.8 MILLION YEAR AGO

SGS and Bavarian Nordic developing challenge strain to combat respiratory virus​

ZURICH SGS and Bavarian Nordic are teaming up to develop a virus challenge strain to combat a common respiratory illness.

SGS and Bavarian Nordic developing challenge strain to combat respiratory virus​

ZURICH, Oct 12 SGS and Bavarian Nordic are teaming up to develop a virus challenge strain to combat a common respiratory illness.

Bavarian Nordic eyes more U.S. government contracts after new vaccine order

COPENHAGEN Danish drug maker Bavarian Nordic expects to win further U.S. contracts for its smallpox vaccine after it secured a key government order, the company said on Thursday.

BRIEF-Bavarian Nordic wins big smallpox vaccine order for U.S. government

* SECURES CONTRACT AWARD FOR SUPPLY OF FREEZE-DRIED IMVAMUNE SMALLPOX VACCINE TO THE U.S. GOVERNMENT

BRIEF-Bavarian Nordic provides update on its RSV vaccine

* REG-BAVARIAN NORDIC PROVIDES UPDATE ON ITS UNIVERSAL RSV VACCINE

BRIEF-Bavarian Nordic says independent Data Monitoring Committee determined continuation of Phase 3 prospect study of Prostvac is futile

* Independent Data Monitoring Committee recommends discontinuation of Bavarian Nordic's Phase 3 study of Prostvac in metastatic prostate cancer

Bavarian Nordic says first milestone payment under J&J deal could be in 2019

COPENHAGEN Danish biotech company Bavarian Nordic expects to get its first milestone payment under a deal with Janssen Pharmaceuticals in 2019, if clinical trials for vaccines targeting hepatitis B and HIV-1 get underway next year, a company executive said.

UPDATE 1-Bavarian Nordic says first milestone payment under J&J deal could be in 2019

* But may take on some risk in respiratory diseases (adds detail on RSV, Prostvac and partnerships)

Select another date: